IFNA1 and neoplasm: In a previous Phase 1 clinical study, we assessed a sequential combination therapy with ropeginterferon alfa-2b (ropeg), a novel polyethylene glycol-conjugated recombinant proline-IFN-α [55,56], and nivolumab in patients with hepatitis B-related HCC who had undergone surgical tumor removal [57].